Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA)
Andreas Tiede, M.D., Ph.D.
Hannover Medical School
Patients with acquired hemophilia (AHA) have adverse events and mortality associated with immunosuppressive therapy. This presentation discusses the findings of an open-label, non-randomized clinical trial that aimed at evaluating the efficacy and safety of emicizumab in patients with acquired hemophilia A not treated with immunosuppressive therapy. This presentation also contains information on the dosing and on clinically relevant bleeds in acquired hemophilia A. Finally, this presentation concludes that emicizumab prevents bleeding patients with acquired hemophilia A and can be used to defer immunosuppressive therapy.